Fatigue, Long COVID, Obstructive Sleep Apnea of Adult
Conditions
Keywords
Post-COVID-19 fatigue Sleep Apnea SARS-CoV-2 Vaccines
Brief summary
Identify the relationship of obstructive sleep apnea (OSA) prevalence with post-COVID-19 fatigue that remains at least six months after acute disease
Detailed description
The presence of fatigue symptoms up to 6-7 months after acute COVID-19 disease, similar to myalgic encephalomyelitis/chronic fatigue syndrome, also observed after other viral infections, have been reported as the most frequent post-COVID-19 symptom (Townsend et al., 2020). There is a physiological plausibility for OSA being a causal factor to COVID-19 morbidity and fatigue symptoms by nocturnal hypoxemia, exacerbating or causing endothelial dysfunction, inflammation, oxidative stress, microaspiration and cardiac dysfunction. OSA activates the renin-angiotensin-aldosterone system (RAAS) and angiotensin-converting enzyme-2 (ACE2), which is the SARS-CoV-2 entry receptor in the cells (Miller et al., 2021). In this study we will identify the prevalence of OSA and it's relation with post-COVID-19 fatigue that remains for at least six month after the acute disease, in patients that attend the post-COVID-19 Out Patients Hospital Clinics. It will be studied also the relation between fatigue and vaccination status, nocturnal hypoxemia, day time sleepness and the acute COVID-19 severity. Data collection will be performed by a questionnaire administered by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation). Demographic, clinical data and clinical research forms will be collected between 6-7th month after the diagnosis of COVID-19 (t1) and 9 months later (t2). Fatigue will be assessed using the Chalder fatigue scale - CFQ-11 (Chalter et al., 1993). The evaluation of OSA related daytime sleepiness will be measured using the Epworth Sleepiness Scale - ESS (Johns, 1991). The OSA diagnosis will be performed using portable monitoring device type III (in-home polygraphy), between 6-7th month after the diagnosis of COVID-19 (t1).
Interventions
OTHEROSA
EXPOSURE TO OBSTRUCTIVE SLEEP APNEA
Sponsors
Sociedade Portuguesa de Pneumologia
Universidade do Algarve
Universidade do Porto
Center for Health Technology and Services Research
Linde Health Care
Centro Hospitalar Universitario do Algarve
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
(1) ≥18 years; (2) previous COVID-19 at least six months before the initial study protocol evaluation; (3) persistent symptoms after cure criteria defined by WHO; (4) patients who attend the post-COVID-19 follow-up consultation of the study centers. (5) SARS-CoV-2 infection confirmed by a positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab (6) patients who agree to sign the Written informed consent (following the ethics committee protocol).
Exclusion criteria
(1) patients who had a concomitant neurological disorder that could increase OSA risk (such as stroke, Parkinson disease, or amyotrophic lateral sclerosis); (2) patients who were on invasive mechanical ventilation. (3) patients with persistent fatigue symptoms,6 months before SARS-CoV-2 infection (4) patients without SARS-CoV-2 positive real-time reverse-transcription polymerase chain reaction on a nasopharyngeal swab
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| post-COVID-19 long term fatigue and OSA | 6 - 7 months | Evaluate if untreated OSA is associated with post COVID-19 long term fatigue. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| post-COVID-19 long term fatigue and daytime sleepiness | 6 - 9 months | Evaluate if daytime sleepiness is associated with post COVID-19 long term fatigue. |
| post-COVID-19 long term fatigue and nocturnal hypoxemia | 6 - 7 months | Evaluate if nocturnal hypoxemia is associated with post COVID-19 long term fatigue |
| post-COVID-19 long term fatigue and severity of acute COVID-19 | 6 - 9 months | Evaluate if severity of acute COVID-19 is associated with post COVID-19 long term fatigue |
| post-COVID-19 long term fatigue and vaccination status | 6 - 9 months | Study the relation between vaccination status and post-COVID-19 long term fatigue |
| Long COVID-19 and OSA impact in quality of life | 6 - 7 months | Study the impact of Long COVID-19 with untreated OSA in quality of life |
Countries
Portugal
Contacts
Primary ContactLigia Pires
Backup ContactTania Fatal
Outcome results
None listed